Key result
In a real-world cohort of patients with cancer-associated VTE treated with edoxaban, the 12-month incidence of VTE recurrence was 3.7%, major bleeding was 12.9%, and all-cause mortality was 38.8%.
Why the study?
Few data exist on the use of edoxaban in cancer-associated venous thromboembolism outside of clinical trials.
What are the real-world outcomes of edoxaban treatment in patients with cancer-associated VTE?
Cohort (n=54)
What are the real-world outcomes of edoxaban treatment in patients with cancer-associated VTE?
In a real-world setting, edoxaban appears effective and safe for cancer-associated VTE, with low rates of VTE recurrence and acceptable bleeding risks, consistent with clinical trial data.
Real-world edoxaban data show low VTE recurrence in cancer-associated thrombosis; leaves open need for randomized confirmation of bleeding safety.
Introduction Few data exist on the use of edoxaban in cancer-associated venous thromboembolism (VTE) outside of clinical trials. Aim of this study was to evaluate the characteristics and outcomes of these patients in a real world clinical setting. Methods We retrospectively analyzed the characteristics of patients with cancer-associated VTE who were prescribed edoxaban. Follow-up at 3, 6, and 12 months was performed: VTE recurrences, bleedings, mortality, cancer progression and treatment, edoxaban interruption and its reason were assessed. Results Fifty-four patients, 38 females (70.4%), mean age 71 ± 14 years, were enrolled. In 38 patients (70.4%), the episode of VTE was the first one, in 28 (51.8%) it was an isolated deep vein thrombosis (DVT), in 13 (24.1%) a pulmonary embolism (PE) associated with DVT, in 13 (24.1%) an isolated PE. Median time between cancer and VTE diagnosis was 6 (interquartile range [IQR] 2–47) months. Median time between VTE diagnosis and edoxaban prescription was 36 (IQR 7–117) days. At 3, 6, and 12 months the incidence of all-cause mortality was 16.6, 22.2, and 38.8%, that of VTE recurrence 1.8, 1.8, and 3.7%, and that of major bleeding 7.4, 9.2, and 12.9%, respectively. No bleeding was fatal. Of the 33 patients alive at 12 months, 32 (96.9%) were still on edoxaban therapy, in seven (21.2%) cancer was in progression. Conclusion Our study, conducted on a real world population of patients with cancer-associated VTE, confirms the results of randomized controlled clinical trials, and supports the use of edoxaban as effective and safe treatment in this context.
No takes yet. Share an insight, caveat, or question.
Grifoni et al. (2022) conducted a cohort in cancer-associated venous thromboembolism (n=54). Edoxaban was evaluated on VTE recurrence at 12 months. In a real-world cohort of patients with cancer-associated VTE treated with edoxaban, the 12-month incidence of VTE recurrence was 3.7%, major bleeding was 12.9%, and all-cause mortality was 38.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: